此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents

2026年6月1日 更新者:Qian Lin、Central South University

A Randomized, Double-blind, Placebo-controlled Study of Akkermansia Muciniphila AKK PROBIO in Improving Obesity and Metabolic Abnormalities in Children and Adolescents Aged 7-18 Years

The problem of obesity among children and adolescents is becoming increasingly serious and may affect their health in adulthood. Researches have found that a type of probiotic in the intestinal tract - "Akkermansia muciniphila" (referred to as AKK), may help regulate metabolism and weight. Although it has shown effects in adults, its safety and efficacy in children and adolescents still need further verification.

This study aims to evaluate the effects of supplementing Akkermansia Muciniphila AKK PROBIO on weight, metabolic health and intestinal flora of obese children and adolescents aged 7 to 18.

研究概览

详细说明

This study aims to evaluate the improvement effect of continuous supplementation with pasteurized inactivated Akkermansia muciniphila (AKK PROBIO) for 12 weeks on the body mass index z-score of obese children and adolescents aged 7 to 18 years, and systematically explore its impact on metabolic health indicators, anthropometric indicators, and sleep, as well as to clarify the safety and tolerance of this intervention. Through the integrated analysis of metagenomics and non-targeted metabolomics, the potential mechanism by which AKK PROBIO regulate the intestinal microbiota and host metabolic profiles in children and adolescents is revealed, providing a scientific basis and biomarker support for the development of precision nutrition intervention strategies for childhood and adolescent obesity.

研究类型

介入性

注册 (估计的)

100

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Hongmei Zhao
  • 电话号码:+86 13975105334
  • 邮箱:364875977@qq.com

学习地点

    • Hunan
      • Changsha、Hunan、中国
        • Xiangya School of Public Health
        • 接触:
        • 接触:
          • Chuxin Wang, Bachelor
          • 电话号码:+86 15367802575
          • 邮箱:45100409@qq.com
        • 副研究员:
          • Di Zhu, Bachelor

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age range: 7 years old to 18 years old (inclusive of boundary values), gender not restricted.
  • Primary obesity: According to the WS/T 586-2018 standard issued by the National Health Commission of China, or the internationally recognized CDC/WHO standard, diagnosed as obesity (if BMI ≥ the 95th percentile of children of the same age and gender).
  • The subjects and their legal guardians understand the research content, voluntarily participate and sign the written informed consent form (for guardians), and the informed consent form (for children aged 8 years and above).
  • Able to comply with the research protocol, complete all visits and sample collection.

Exclusion Criteria:

  • Have a definite endocrine disorder causing obesity (such as Cushing's syndrome, hypothyroidism), a genetic syndrome (such as Prader-Willi syndrome), or other known organic diseases.
  • Have a severe primary disease of the liver, kidney, cardiovascular system, respiratory system or hematopoietic system, etc.
  • Have used antibiotics, probiotics, prebiotics or synbiotic products within 3 months prior to screening.
  • Have a history of systemic use of glucocorticoids or other drugs that may affect weight and metabolism (such as metformin, systemic glucocorticoids, diuretics, etc.) within 1 month prior to screening.
  • Subjects are allergic to any component of the study product (AKK probiotic capsules or placebo).
  • Subjects are participating in other clinical trials.
  • Have a history of severe gastrointestinal diseases, such as inflammatory bowel disease (IBD).
  • Other conditions as determined by the researcher to be unsuitable for participation in this study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo Group

Placebo group (n=50): The subjects took one placebo capsule (containing inert ingredients such as maltodextrin) identical in appearance and taste to the AKK probiotic capsules before each breakfast and dinner every day for 12 consecutive weeks. After the study ended, the subjects in the placebo group could receive the same dose and specification of AKK probiotic capsules.

Basic intervention: During the study period, both groups of subjects would receive unified and standardized health education, including the principles of balanced diet provided by registered dietitians and the physical activity suggestions provided by exercise rehabilitation specialists.

Placebo group (n=50): The subjects took one placebo capsule (containing inert ingredients such as maltodextrin) identical in appearance and taste to the AKK probiotic capsules before each breakfast and dinner every day for 12 consecutive weeks. After the study ended, the subjects in the placebo group could receive the same dose and specification of AKK probiotic capsules.
实验性的:AKK Group

This intervention trial intends to use pasteurized AKK PROBIO, with each dose containing the equivalent of 30 billion inactivated bacterial cells. AKK PROBIO is a research hotspot in the field of intestinal microecology. The pasteurized AKK PROBIO (belonging to prebiotics) have been proven to have good safety and metabolic improvement effects in adults. Compared to live bacterial preparations, the inactivated form has higher stability, a longer shelf life, and better safety.

AKK group (n=50): The subjects take one AKK probiotic capsule orally before each breakfast and dinner every day, and the intervention lasted for 12 weeks.

During the study period, both groups of participants will receive unified and standardized health education, which includes the principles of balanced diet provided by registered dietitians and the suggestions for physical activities provided by exercise rehabilitation specialists.

This intervention trial intends to use pasteurized AKK PROBIO, with each dose containing the equivalent of 30 billion inactivated bacterial cells. AKK PROBIO is a research hotspot in the field of intestinal microecology. The pasteurized AKK PROBIO (belonging to prebiotics) have been proven to have good safety and metabolic improvement effects in adults. Compared to live bacterial preparations, the inactivated form has higher stability, a longer shelf life, and better safety. AKK group (n=50): The subjects take one AKK probiotic capsule orally before each breakfast and dinner every day, and the intervention lasted for 12 weeks. During the study period, both groups of participants will receive unified and standardized health education, which includes the principles of balanced diet provided by registered dietitians and the suggestions for physical activities provided by exercise rehabilitation specialists.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Z - score
大体时间:During the baseline period (T0), the middle period (T1, 6 weeks), and the end of the intervention (T2, 12weeks)

The Z-score for children (Z-score) is a statistical indicator that measures the deviation of children's growth indicators such as height (in meters), weight (in kilograms), and BMI (in kg/m^2) from the reference population of the same age and gender. It is used to assess nutritional status and growth development levels.

The nutritional status can be judged by evaluating the height-for-age z-score (HAZ), weight-for-age Z-score (WAZ), and weight-for-height z-score (WHZ) of children and BMI-for-age Z-score (BMIZ).

The Z-score formula is: Z = (Measured value - Average value of the reference population) / Standard deviation of the reference population.

Standard: ±2 : Normal range (95% healthy children)

  • -2 ≤ Z < -1: Less than Normal
  • Z < -2: Growth retardation, low weight or emaciation (<-3 is severe)
  • +1 ≤ Z ≤ +2: Overweight
  • +2 ≤ Z ≤ +3: Obesity
  • Z > +3: Severe obesity
During the baseline period (T0), the middle period (T1, 6 weeks), and the end of the intervention (T2, 12weeks)

次要结果测量

结果测量
措施说明
大体时间
Dietary intake
大体时间:At the baseline (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)

The dietary intake of the research subjects was understood through 24-hour recall and food frequency questionnaires (for the past month). The dietary and nutrient intake of the research subjects was evaluated through food diversity scores and the intake of energy and nutrients(converts the weekly intake volume (ml/g) into "servings per week").

A designed dietary frequency questionnaire was used to evaluate the regular and environmental dietary behaviors of adolescents in the past three months. The questionnaire is based on common dimensions of dietary behavior and mainly covers five core behavioral categories: having breakfast, having a late-night snack, having meals at school, eating alone, and using food delivery platforms. The frequency options for each category are "Never", "once a month or less", "2 to 3 times a month", "once a week", "2 to 3 times a week", "4 to 5 times a week", "once a day", "twice a day", and "three or more times a day".

At the baseline (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
Sleep quality (13- 18 years)
大体时间:At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)

The Pittsburgh Sleep Quality Index (PSQI) in Chinese was used to assess the subjective sleep quality of participants aged 13 to 18 years. This scale consists of 19 self-rated items and 5 other-rated items, and the scoring can yield 7 scoring items including sleep latency, sleep disorders, sleep quality, sleep duration, hypnotic drugs, sleep efficiency and daytime function.

Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties.

The evaluation of different dimensions of the scale will be separately described.

At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
Sleep quality (7- 12 years)
大体时间:At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)

For children aged 7 to 12 years, the sleep questionnaire items were designed based on the CSHQ (Children's Sleep Habits Questionnaire). It consists of 48 items (33 scoring items), and can assess specific sleep problems in eight aspects: poor sleep habits, sleep anxiety, irregular sleep duration, sleep breathing disorders, abnormal sleep patterns, daytime sleepiness, night awakenings, and prolonged sleep latency.

CSHQ requires parents to recall their child's sleep patterns over the past 4 weeks, and to select the sleep condition that best represents the typical week for a 3-point Likert scale rating of "often" (5-7 times per week), "sometimes" (2-4 times per week), and "rarely" (0-1 time per week).

At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
Gastrointestinal symptoms
大体时间:At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)

Gastrointestinal symptoms will be evaluated using the Gastrointestinal Symptom Rating Scale (GSRS).

The GSRS is a specific scale consisting of 15 items , with each item scored from 1 (no symptoms at all) to 7 (extremely severe symptoms). The GSRS was used to assess the occurrence of gastrointestinal symptoms in the subjects over the past week, covering five types of digestive tract symptoms: reflux syndrome, abdominal pain syndrome, dyspepsia, diarrhea syndrome, and constipation syndrome. The total score is the sum of all items, with a higher score indicating a more severe condition.

At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)
Stool Classification
大体时间:At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)

The Bristol Stool Classification Scale (BSFS) was used to evaluate the type of stool. The BSFS is a widely used scale for assessing intestinal motility and can be used to understand the type of stool of the subjects over the past week. This scale presents the transformation from hard stool to watery stool through pictures of types one to seven.

The seven types of stool are:

Type 1: Separate hard lumps, like nuts (difficult to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft (average stool) Type 5: Soft blobs with clear cut edges Type 6: Fluffy pieces with ragged edges, a mushy stool (diarrhea) Type 7: Watery, no solid pieces, entirely liquid (diarrhea)

At the baseline period (T0), mid-term (T1, 6weeks), and the end of the intervention (T2, 12weeks)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Qian Lin, Doctor、Xiangya School of Public Health, Central South University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月6日

初级完成 (估计的)

2026年12月20日

研究完成 (估计的)

2027年2月12日

研究注册日期

首次提交

2026年4月22日

首先提交符合 QC 标准的

2026年5月15日

首次发布 (实际的)

2026年5月18日

研究记录更新

最后更新发布 (实际的)

2026年6月3日

上次提交的符合 QC 标准的更新

2026年6月1日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅